- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05106361
MOSAIC (MOthers' AdvocateS In the Community) for Pregnant Women and Mothers of Children Under 5 With Experience of Intimate Partner Violence (MOSAIC Plus)
MOSAIC (MOthers' AdvocateS In the Community) for Pregnant Women and Mothers of Children Under 5 With Experience of Intimate Partner Violence: Randomized Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Violence against women is a global human rights concern and a significant public health challenge; 1 in 3 three women experience lifetime physical and/or sexual violence.1 As many as 5.3 million U.S. women report experiencing intimate partner violence (IPV; referring to sexual or physical violence by current or former partners) annually2. Depression and posttraumatic stress disorder (PTSD) are the two most common mental health consequences of IPV. In turn, developing depressive and PTSD symptoms after experiencing IPV increases future risk of IPV3. IPV is also associated with chronic physical health problems4,5 and self-harm 6.
Motherhood and pregnancy increase the risk for prolonged exposure to physical, psychological and sexual IPV7. With as many as 4% to 8% of pregnant women reporting IPV during pregnancy, IPV can start or worsen during the perinatal period8. Previous and current experience of IPV is strongly associated with poor physical health, mental health and obstetric outcomes9,10; leading to increased utilization of health services11 even after the IPV ends12. There are very few interventions that effectively reduce IPV among pregnant women and mothers with children under 5 who report IPV13-15. One of them, Mother AdvocateS In the Community (MOSAIC) forms the basis of this proposal16. No existing intervention addresses the depressive and PTSD symptoms that often follow IPV, are associated with suffering and morbidity, and potentiate future IPV risk for pregnant women and mothers with children under 5 who report IPV. In fact, there are not any interventions for any group of women that effectively reduce both future IPV risk and common related mental health symptoms such as depression and PTSD. An integrated intervention that addresses elevated symptoms of maternal depression and PTSD while reducing subsequent IPV is needed.
MOSAIC is a non-professional intervention delivered by mentor mothers from the community to reduce IPV in pregnant women and mothers with children under 517. The intervention combines elements of mentoring and IPV-specific support provided by mentor mothers. MOSAIC was also tested in a fully-powered RCT for pregnant women and mothers with children under 5 in Australia and found to reduce subsequent IPV15. However, it did not significantly improve depression, and PTSD symptoms were not evaluated. Given the suffering, morbidity, and additional risk of IPV conferred by depressive and PTSD symptoms, the proposed study will augment MOSAIC with principles of an evidence-based intervention to improve maternal mental health. Interpersonal psychotherapy (IPT) is the front-line treatment for maternal depression18 and has been found to reduce PTSD symptoms in the perinatal period19. IPT addresses maternal mental health by helping women increase their general social support systems and build communication skills and confidence to access needed resources and help. IPT can be effectively delivered by lay providers. This proposal will integrate IPT principles into MOSAIC to address both IPV and its mental health sequelae.
The purpose of this R34 exploratory research proposal is to conduct formative work for a larger randomized controlled trial (RCT) evaluating the effectiveness of the "Mother AdvocateS In the Community (MOSAIC) Plus" intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms. The proposed study will enroll pregnant women who report experience of IPV in the past 6 months, and who screen positive for elevated depressive and/or PTSD symptoms. The intervention lasts 9 months after enrollment. Women will be recruited from Obstetrics and Gynecological unit of the Hurley Medical Center and YWCA, Flint. The control condition will be the original MOSAIC intervention. Study assessments will take place at baseline, 3, 6 and 9 months.
The development aims of this proposal are to:
- Enhance and expand the MOSAIC manual (designed to be delivered by lay providers) with lay-provider friendly IPT principles for reducing depressive and PTSD symptoms.
- Refine the manual, intervention, and study procedures using 6 focus groups: 3 groups with mothers who have experienced IPV in the past 6 months (n~20), 2 with potential mentor mothers (n~16), and 1 group with nurse-family partnership staff (n~8)
- Develop, implement, and evaluate the intervention training program.
Improve the clarity, content, acceptability, and feasibility of the enhanced MOSAIC Plus intervention through a small open trial (n = 15) of mothers with past 6-month IPV experience
The pilot study aims of this proposal are to:
Conduct a pilot RCT in a sample of 40 mothers with IPV experience in the past 6 months to demonstrate the feasibility and acceptability of the proposed recruitment methods, research design, intervention training methods, and of delivering the MOSAIC Plus and MOSAIC interventions. As recommended by NIMH, we will also examine 95% confidence intervals around differences between the proposed intervention and MOSAIC for the following outcomes through 9 months after baseline:
- Mental health outcomes. Reduction in depressive (primary) and PTSD symptoms
- IPV outcomes. Decreased subsequent IPV over the 9 months measured by CAS
- Functioning outcomes. Improvement in functioning, self-care and general health and wellbeing
- Potential target mechanisms. Increased social support and effectiveness obtaining resources.
Interventions to improve mental health challenges experienced by mothers who experienced IPV are of great public health significance. Reducing depressive and PTSD symptoms in women with the experience of IPV has significant public health benefits for mothers and their children.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maji H Debena, PhD
- Phone Number: 810-600-5684
- Email: debenama@msu.edu
Study Locations
-
-
Michigan
-
Flint, Michigan, United States, 48502
- YWCA Flint
-
Contact:
- Trina Sanders
- Email: trinasanders@ywcaflint.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pregnant and/or are mothers of children under 5 and r
- Report IPV experiences in the past 6 months (as assessed by Composite Abuse Scale)
- Aged 18 or above,
- Have elevated depressive and/or PTSD symptoms as assessed by Patient Health Questionnaire (PHQ-9) with a cutoff point of ≥9, and/or the Davidson Trauma Scale (DTS) with a cut-off point of ≥40.
Exclusion Criteria:
- Cannot provide the name and contact information of at least two locator persons,
- Do not have access to any telephone,
- Cannot understand English well enough to understand the consent form or assessment instruments when they are read aloud
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MOSAIC Plus
"Mother AdvocateS In the Community (MOSAIC) Plus" intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV.
The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms.
|
Those in the experimental arm will receive the intervention is called "Mother AdvocateS In the Community (MOSAIC) Plus", an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV.
The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms.
|
Active Comparator: MOSAIC
Those in the active comparator will receive the "Mother AdvocateS In the Community (MOSAIC) Plus" intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV.
|
Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC).
This does not include the IPT component.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
acceptability
Time Frame: 9 months
|
We will evaluate the acceptability of the proposed recruitment methods, research design, intervention training methods, and of delivering the MOSAIC Plus and MOSAIC interventions by using End of Treatment Questionnaire.
|
9 months
|
Satisfaction with care
Time Frame: 9 months
|
We will evaluate the feasibility of the proposed recruitment methods, research design, intervention training methods, and of delivering the MOSAIC Plus and MOSAIC interventions by using Client Satisfaction Questionnaire.
|
9 months
|
Quality of Working Relationship
Time Frame: 9 months
|
We will evaluate therapeutic alliance by using Working Alliance Inventory-Short Revised (WAI-SR)
|
9 months
|
Reduction in depressive symptoms
Time Frame: baseline, 3, 6 and 9 months
|
We will measure reduction in depressive symptoms as assessed by Patient Health Questionnaire (PHQ-9).
|
baseline, 3, 6 and 9 months
|
Reduction in Posttraumatic Stress Disorder Symptoms
Time Frame: baseline, 3, 6 and 9 months
|
We will measure reduction in posttraumatic stress disorder symptoms by using Davidson Trauma Scale.
|
baseline, 3, 6 and 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intimate Partner Violence
Time Frame: baseline, 3, 6 and 9 months
|
We will measure reduction in subsequent intimate partner violence by using Composite Abuse Scale.
|
baseline, 3, 6 and 9 months
|
Effectiveness Obtaining Resources
Time Frame: baseline, 3, 6 and 9 months
|
We will measure effectiveness in obtaining resources by using Effectiveness Obtaining Resources (EOR) scale.
|
baseline, 3, 6 and 9 months
|
Perceived Social Support
Time Frame: baseline, 3, 6 and 9 months
|
We will measure improvements in perceived social support by using The RAND social support scale (Medical Outcome Study-Social Support Survey MOS-SS)
|
baseline, 3, 6 and 9 months
|
Functioning
Time Frame: baseline, 3, 6 and 9 months
|
We will use the WHO Disability Assessment schedule-12 to assess mental health related disability.
|
baseline, 3, 6 and 9 months
|
Self-care and self-worth
Time Frame: baseline, 3, 6 and 9 months
|
We will use the self-care and self-worth scale to assess changes in self-care.
|
baseline, 3, 6 and 9 months
|
General health and wellbeing
Time Frame: baseline, 3, 6 and 9 months
|
We will use the SF-36 to assess changes in general health and wellbeing.
|
baseline, 3, 6 and 9 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Provider Competencies
Time Frame: 6 and 9 months
|
We will assess competency of providers by using Competency Assessment Inventory (CAI)
|
6 and 9 months
|
Quality of working relationship-provider perspective
Time Frame: 3, 6 and 9 months
|
We will assess the quality of working relationship by using the provider perspective section of working alliance inventory.
|
3, 6 and 9 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 351185
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on MOSAIC Plus
-
Michigan State UniversityNot yet recruitingDepression | Intimate Partner Violence | Posttraumatic Stress Symptom
-
LUTRONIC CorporationRecruitingAcne Vulgaris | Scar | Wrinkle | Photoaging | Skin Texture Disorder | Hair Loss | Stretch MarkUnited States
-
Colorado Center for Reproductive MedicineRecruiting
-
Janssen Vaccines & Prevention B.V.Beth Israel Deaconess Medical Center; US Military HIV Research Program; Ragon...CompletedHuman Immunodeficiency VirusUnited States
-
Janssen Vaccines & Prevention B.V.CompletedHealthyUnited States, Rwanda, Kenya
-
Crucell Holland BVNational Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaboratorsCompleted
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; The Dunhill Medical TrustUnknownPeripheral Arterial Disease | Intermittent Claudication | Peripheral Vascular DiseaseUnited Kingdom
-
University Hospital Plymouth NHS TrustCompletedCardiac Valve ReplacementUnited Kingdom
-
Medtronic Bakken Research CenterCompletedCoronary Artery Bypass Grafting | Aortic Valve ReplacementBelgium, Israel, Germany, Austria, Italy
-
MejoraVisionMDMaisonneuve-Rosemont Hospital; Retina and Genomics InstituteRecruitingRetinitis Pigmentosa | Usher Syndromes | Cone Dystrophy | Retina; DystrophyMexico